Skip to content

Metabolomics Study of Rheumatoid Arthritis in Active and Remission Periods

Mechanisms of targeting FGFR1 for rheumatoid arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095841
Enrollment
Unknown
Registered
2025-01-14
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Active RA group:None
Remission RA group:None
Healthy control group:None

Sponsors

Wuxi Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.RA patients should meet the diagnostic criteria of RA, and the test results of rheumatoid factor and anti-cyclic citrullinated peptide antibody should be double positive; 2.Patients with OA should meet the diagnostic criteria of KOA, and the X-ray Kellgren classification should be III-IV; 3.Healthy people need to meet the body mass index BMI of 19-26kg/m^2, male weight>50kg, female weight>45kg, no blood donation in the last three months, and the results of physical examination report show that the health of the eligible person; 4.Age requirement is between 18 and 80 years old, gender is not limited; 5.Patients are required to voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Digestive system and kidney diseases, neuromuscular diseases, malignant diseases such as multiple myeloma, a variety of congenital and acquired bone metabolism anomaly diseases, long-term use of glucocorticoids or other drugs that affect bone metabolism; 2.Patients suffering from serious cardiovascular, pulmonary, hepatic, renal, haematological or psychiatric diseases; or those with serious abnormalities of the main indexes in the admission examination; 3.Patients with other rheumatic diseases in combination or with acute and chronic inflammatory diseases or infectious diseases; 4.Presence or history of malignant tumour; 5.History of joint infection. 6.Pregnant or breastfeeding women; 7.Those with a history of alcohol and drug abuse. 8.Those who are undergoing or have recently undergone clinical trials of disease medications.

Design outcomes

Primary

MeasureTime frame
Serum metabolomics;

Secondary

MeasureTime frame
ESR;CRP;Rheumatoid factor;Anti-CCP antibodies;Glutamine aminotransferase (GATT);Glutamic transaminase (GST);Creatinine;Urea nitrogen;Blood sugar;Blood lipid;

Countries

China

Contacts

Public ContactMeng Xiaohui

Wuxi Traditional Chinese Medicine Hospital

drxiaohuimeng@outlook.com+86 185 5219 0622

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026